Melloni Chiara, Peterson Eric D, Chen Anita Y, Szczech Lynda A, Newby L Kristin, Harrington Robert A, Gibler W Brian, Ohman E Magnus, Spinler Sarah A, Roe Matthew T, Alexander Karen P
Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA.
J Am Coll Cardiol. 2008 Mar 11;51(10):991-6. doi: 10.1016/j.jacc.2007.11.045.
Our purpose was to compare formulae for estimating glomerular filtration rate (GFR) in non-ST-segment elevation acute coronary syndromes (NSTE ACS) patients.
Assessment of GFR is important for antithrombotic dose adjustment in NSTE ACS patients.
We assessed estimated glomerular filtration rate (eGFR) with Cockcroft-Gault (C-G) and Modification of Diet in Renal Disease (MDRD) formulae in 46,942 NSTE ACS patients from 408 CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines) hospitals. Formula agreement was shown continuously and by chronic kidney disease (CKD) stages. We determined in-hospital outcomes and the association between antithrombotic dose adjustment and bleeding for moderate CKD as determined by each formula.
The median (interquartile range [IQR]) eGFR was 53.2 ml/min (34.7, 75.1 ml/min) by C-G and 65.8 ml/min (47.6, 83.5 ml/min) by MDRD. The mean eGFR was higher with MDRD (approximately 9.1 ml/min), but this difference was greater in age, weight, and gender subgroups. Chronic kidney disease classification differed in 20% of the population and altered when antithrombotic dose adjustment was required by C-G versus MDRD (eptifibatide: 45.7% vs. 27.3%; enoxaparin: 19.0% vs. 9.6%).
Important CKD disagreements occur in approximately 20% of acute coronary syndrome patients, affecting dosing adjustments in those already susceptible to bleeding. Dosing based on C-G formula is preferable, particularly in the small, female, or elderly patient.
我们的目的是比较用于估算非ST段抬高型急性冠脉综合征(NSTE ACS)患者肾小球滤过率(GFR)的公式。
评估GFR对于NSTE ACS患者的抗栓剂量调整很重要。
我们使用Cockcroft-Gault(C-G)公式和肾脏病饮食改良(MDRD)公式,对来自408家CRUSADE(不稳定型心绞痛患者快速风险分层能否通过早期实施美国心脏病学会/美国心脏协会指南抑制不良结局)医院的46942例NSTE ACS患者的估算肾小球滤过率(eGFR)进行了评估。通过连续变量以及慢性肾脏病(CKD)分期展示了公式的一致性。我们确定了院内结局以及每种公式所确定的中度CKD患者抗栓剂量调整与出血之间的关联。
C-G公式得出的eGFR中位数(四分位间距[IQR])为53.2 ml/分钟(34.7,75.1 ml/分钟),MDRD公式得出的为65.8 ml/分钟(47.6,83.5 ml/分钟)。MDRD公式得出的平均eGFR更高(约9.1 ml/分钟),但在年龄、体重和性别亚组中这种差异更大。20%的人群中CKD分类不同,并且当C-G公式与MDRD公式需要进行抗栓剂量调整时会发生改变(依替巴肽:45.7%对27.3%;依诺肝素:19.0%对9.6%)。
约20%的急性冠脉综合征患者中出现了重要的CKD判断分歧,影响了那些本就容易出血患者的剂量调整。基于C-G公式给药更可取,尤其是在体型小、女性或老年患者中。